Clinical Trial Update: Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study [Phase 4]

View source ↗

Summary

A Phase 4 dose-escalation study assessing tofacitinib for refractory axial spondyloarthritis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Conditions: Axial Spondyloarthritis | Phase 4 | Status: COMPLETED